Timosina Alfa-1: what it is and what the evidence says
A peptide studied for its relationship with modulation of the immune response and balance of the body defenses.
Last reviewed: August 16, 2026 · How we verify this
The ground it plays on
The immune system is not something you turn "up" or "down": it is regulated. A compound that raised the response without control would be a problem, not a benefit, which is why the correct word is modulation. For people with autoimmune or inflammatory conditions, this stops being a technical nuance.
What it is studied for
Immune support, balance, recovery.
There is a distinction that almost always gets lost. A compound being studied for something is not the same as achieving it. And even where it works in a dish or in a mouse, that says little about whether it works in a person or whether the benefit is worth the risk. The section below therefore carries more weight than everything above it.
What the human evidence says
It is among the best studied: it is marketed in several countries and has real randomized trials in chronic hepatitis B and in sepsis, although the results are uneven.
The limitation that matters most
The phase 3 TESTS trial (BMJ, 2025) did NOT find a reduction in 28-day mortality in sepsis, so the earlier favorable meta-analyses rested mainly on small studies and were not confirmed in the large trial.
Regulatory status
Registered in several countries as Zadaxin; not approved by the FDA.
Status can change and varies by country. Always verify the rules in force where you live before drawing conclusions.
Cautions and context
Affects immune function; clinical context is decisive.
With immune or autoimmune conditions, professional supervision is mandatory.
What this page cannot give you
A reference page can take you this far. You know what Timosina Alfa-1 is and where its research stands, which already puts you ahead of most readers. Four questions remain that no encyclopedia can answer for you, because the answers depend on your own situation:
- What would you measure beforehand, so that later you could tell whether anything actually changed?
- What would you watch along the way, and how consistently?
- What would you ask a professional, and in how much detail, so you do not walk out with a textbook answer?
- What would make you stop?
That is what the course is for
PeptiXtreme is ${CIF.LECCIONES} lessons that hand out no numbers. Each one ends with your starting point, what to watch along the way, the specific questions you take to a professional and the signals that mean stop. It includes per-module exams, a diploma with a verifiable folio, a record to track how you progress, and a human advisor you can actually write to.
See the course → Or measure your judgment, freeReferences
Every entry links to its record on PubMed, the US National Library of Medicine database. Open them and check. We would rather have a reader who verifies than one who takes our word for it.
- The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trialhuman BMJ · 2025 · PMID 39814420 →
- The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trialhuman J Viral Hepat · 2005 · PMID 15850471 →
- The efficacy of thymosin α1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials BMC Infect Dis · 2016 · PMID 27633969 →
- Thymosin alpha1 based immunomodulatory therapy for sepsis: a systematic review and meta-analysis Int J Infect Dis · 2015 · PMID 25532482 →
- Efficacy of thymosin α1 for sepsis: a systematic review and meta-analysis of randomized controlled trials Front Cell Infect Microbiol · 2025 · PMID 40969554 →
- Thymosin alpha 1: past clinical experience and future promisereview Ann N Y Acad Sci · 2010 · PMID 20536460 →
- Thymosin alpha-1review Am J Health Syst Pharm · 2001 · PMID 11381492 →
Was this page useful?
Research moves, and when something relevant changes we update the page. If you want to hear about it for Timosina Alfa-1 or any other compound, leave your email. The introductory guide comes with it. No spam, no list-selling; one click to unsubscribe.
Frequently asked questions
What is Timosina Alfa-1?
A peptide studied for its relationship with modulation of the immune response and balance of the body defenses. It is studied within the area of immune.
Is there human evidence for Timosina Alfa-1?
It is among the best studied: it is marketed in several countries and has real randomized trials in chronic hepatitis B and in sepsis, although the results are uneven.
Is it approved by any health agency?
Registered in several countries as Zadaxin; not approved by the FDA.
What is the dose of Timosina Alfa-1?
We do not publish dosages. This is not an oversight. No single figure works for everyone: the regimen depends on a person's medical history, on whatever medication they already take, and on the goal they are chasing, which is something a professional weighs with the case in front of them. What you can build is the ability to walk into that appointment knowing what to ask.
Where can I learn to evaluate this properly?
This page tells you what Timosina Alfa-1 is and what the evidence says. The PeptiXtreme course teaches the other half: what you would measure before considering anything, what you would watch, the specific questions you would take to a professional and when you would stop.